Literature DB >> 17662770

The association between saphenous vein endothelial function, systemic inflammation, and statin therapy in patients undergoing coronary artery bypass surgery.

Aziz Momin1, Narbeh Melikian, Stephen B Wheatcroft, David Grieve, Lindsay C John, Ahmad El Gamel, Michael T Marrinan, Jatin B Desai, Catherine Driver, Roy Sherwood, Ajay M Shah, Mark T Kearney.   

Abstract

OBJECTIVES: Endothelial dysfunction and C-reactive protein play a pivotal role in development of atherosclerosis and act as markers for future adverse cardiac events. Statins reduce C-reactive protein levels and improve endothelial function. However, little information is available on endothelial function and its determinants in veins. We investigated the association between saphenous vein endothelial function and C-reactive protein levels in patients treated with statins undergoing coronary artery bypass surgery.
METHODS: Seventy-six patients with optimal low-density lipoprotein cholesterol levels (< or =1.6 mmol/L) secondary to regular treatment with a minimum of simvastatin 40 mg were recruited. Each subject underwent detailed characterization according to anthropomorphic data, saphenous vein endothelial function (assessed ex vivo by measuring acetylcholine-induced relaxation of venous rings), and markers of systemic inflammation (C-reactive protein and tumor necrosis factor-alpha).
RESULTS: Despite regular treatment with statins, 26% of patients had C-reactive protein levels in the "high-risk" range (>3.0 mg/L). There was a negative linear correlation between acetylcholine-induced venous relaxation and C-reactive protein (r = -.30, P = .02) and waist circumference (r = -0.21, P = .03). In a multivariate regression model, C-reactive protein (P = .02) was the only independent predictor of acetylcholine-induced venous relaxation. In turn, correlates of C-reactive protein were assessed. There was a correlation between C-reactive protein and coronary atherosclerotic burden (r = .46, P < .0001), body mass index (r = .26, P = .03), fasting glucose levels (r = .31, P = .01), and waist circumference (r = .29, P = .01). Using multivariate analysis, coronary atherosclerotic burden (P < .0001) was the only independent predictor of C-reactive protein.
CONCLUSIONS: In our cohort of patients with coronary artery disease, C-reactive protein level was the only independent predictor of saphenous vein endothelial function. In turn, its levels were independently influenced by the extent of coronary atherosclerotic burden.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17662770     DOI: 10.1016/j.jtcvs.2006.12.064

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  5 in total

1.  Early remodeling of lower extremity vein grafts: inflammation influences biomechanical adaptation.

Authors:  Christopher D Owens; Frank J Rybicki; Nicole Wake; Andres Schanzer; Dimitrios Mitsouras; Marie D Gerhard-Herman; Michael S Conte
Journal:  J Vasc Surg       Date:  2008-04-28       Impact factor: 4.268

Review 2.  Should C-reactive protein be a target of therapy?

Authors:  Jisun Oh; Hwee Teoh; Lawrence A Leiter
Journal:  Diabetes Care       Date:  2011-05       Impact factor: 19.112

3.  Metabolomic analyses for atherosclerosis, diabetes, and obesity.

Authors:  Fuyong Du; Anthony Virtue; Hong Wang; Xiao-Feng Yang
Journal:  Biomark Res       Date:  2013-04-01

4.  Mechanotransduction in Coronary Vein Graft Disease.

Authors:  Matthijs Steven Ruiter; Maurizio Pesce
Journal:  Front Cardiovasc Med       Date:  2018-03-14

5.  Statins in patients with COVID-19: a retrospective cohort study in Iranian COVID-19 patients.

Authors:  Payam Peymani; Tania Dehesh; Pooneh Mokarram; Saeid Ghavami; Farnaz Aligolighasemabadi; Mohammadamin Sadeghdoust; Katarzyna Kotfis; Mazaher Ahmadi; Parvaneh Mehrbod; Pooya Iranpour; Sanaz Dastghaib; Ahmad Nasimian; Amir Ravandi; Biniam Kidane; Naseer Ahmed; Pawan Sharma; Shahla Shojaei; Kamran Bagheri Lankarani; Andrzej Madej; Nima Rezaei; Tayyebeh Madrakian; Marek J Los; Hagar Ibrahim Labouta
Journal:  Transl Med Commun       Date:  2021-01-25
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.